Personalised Medicine and Biopharma Shakti
Context:
During a recent webinar on "Biotech Education in Personalised Medicine," experts highlighted that India is poised to become a global biopharma manufacturing hub.
This follows the Union Budget 2026-27 announcement of a massive ₹10,000 crore investment in the biotechnology sector.
Biopharma Shakti Initiative:
The budget introduced a new initiative called "Biopharma Shakti" aimed at boosting the production of biologics and biosimilars.
This initiative is expected to create significant opportunities for professionals in the biotechnology sector, supported by growing healthcare demand and government investment.
Shift to Personalised Medicine:
Medical treatments are undergoing a fundamental transition from "reactive and standardised" approaches to "proactive and individualised" treatments.
Basis of Treatment:
Instead of a "one-size-fits-all" model, therapies will now be tailored based on a patient’s:
Genetic and metabolic profile.
Lifestyle and ethnic profile.
Regional and seasonal factors.
Role of Technology:
The evolution of personalised medicine is driven by the integration of genomics, bioinformatics, and data science.
These technologies facilitate precise diagnosis, targeted therapies, and optimised drug selection and dosage.
Future Outlook:
Industry 5.0:
Biotechnology’s will have a central role within Industry 5.0, emphasising human-centric innovations and sustainability.
Skills Required:
Future drug development will rely heavily on computational biology, programming, and the analysis of large datasets, making these critical skills for the next generation of scientists.